Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.30 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.30 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18557387 | 0.65 | SMN1; SMN2 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12107731 | 0.65 | HDAC3 (0.36) | FOLH1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16307671 | 0.65 | TP53 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12799291 | 0.64 | HTT (0.35) | FOLH1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL23900960 | 0.63 | HDAC3 (0.36) | FOLH1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL18466198 | 0.63 | HDAC3 (0.41) | FOLH1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL24708055 | 0.62 | MTNR1A (0.38) | FOLH1 | |
| SCHEMBL15725708 | 0.62 | FOLH1 (0.34) | FOLH1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL24974779 | 0.61 | ANO1 (0.31) | — | |
| SCHEMBL13056339 | 0.61 | SMN1; SMN2 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | FOLH1 867/4885HDAC3 2964/4885HDAC4 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.